Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.

摘要: Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are effective in treatment of metastatic colorectal cancer. Cetuximab is a human-murine chimeric monoclonal antibody EGFR. Even with premedication, cetuximab can result an infusion reaction select patients. In portion these patients, severe, and further therapy contraindicated, thus preventing patients from receiving potentially beneficial anti-EGFR therapy. Panitumumab fully human also given without premedication and, clinical trials, has rarely been associated reactions. It not yet known whether panitumumab be safely previous severe to cetuximab. We report case patient successfully treated after had